{"gene":"GPC2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1994,"finding":"Cerebroglycan (GPC2) is a glycosylphosphatidylinositol (GPI)-anchored heparan sulfate proteoglycan (HSPG) with a predicted molecular mass of 58.6 kD and five potential heparan sulfate attachment sites. Together with glypican, it defines a family of integral membrane HSPGs characterized by GPI linkage and a conserved pattern of 14 cysteine residues. Expression is restricted to the developing nervous system, appearing transiently in immature neurons around the time of final mitosis and disappearing after cell migration and axon outgrowth.","method":"Molecular cloning, sequence analysis, in situ hybridization","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — molecular cloning with structural characterization (predicted domains, GPI anchor, cysteine pattern) plus in situ hybridization expression pattern; foundational characterization paper replicated by subsequent studies","pmids":["8294498"],"is_preprint":false},{"year":1997,"finding":"Cerebroglycan (GPC2) protein is strongly polarized to axons and growth cones of developing neurons, excluded from the somatodendritic compartment, and is present on axon tracts during active axon growth but absent after axons reach their targets, consistent with a role in axon growth or guidance.","method":"Monospecific antibody localization by immunohistochemistry in vivo and in vitro; analysis of hippocampal neurons at defined developmental stages","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein localization with monospecific antibodies in multiple tissue contexts, single lab","pmids":["9133438"],"is_preprint":false},{"year":2017,"finding":"GPC2 expression in neuroblastoma is driven by MYCN transcriptional activation and/or somatic gain of the GPC2 locus. GPC2 is required for neuroblastoma cell proliferation, as demonstrated by loss-of-function experiments showing reduced proliferation upon GPC2 knockdown.","method":"RNA sequencing, somatic copy-number analysis, MYCN transcriptional activation assays, loss-of-function (knockdown) with proliferation readout","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (transcriptomics, genomics, functional knockdown), single lab","pmids":["28898695"],"is_preprint":false},{"year":2021,"finding":"The GPC2-directed antibody D3 binds a conformational, tumor-specific epitope on the extracellular domain of GPC2, as determined by crystal structure of the D3-GPC2-Fab/GPC2 complex at 3.3 Å resolution. The ADC (D3-GPC2-PBD) induces DNA damage, apoptosis, and bystander cell killing in neuroblastoma and small-cell lung cancer cells.","method":"Crystal structure determination at 3.3 Å; in vitro and in vivo cytotoxicity assays with DNA damage and apoptosis readouts","journal":"Cell reports. Medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional validation (ADC mechanism via DNA damage/apoptosis), multiple orthogonal assays in single rigorous study","pmids":["34337560"],"is_preprint":false},{"year":2022,"finding":"D3-GPC2-PBD ADC induces immunogenic cell death (ICD) in GPC2-expressing neuroblastoma cells, evidenced by calreticulin and HSP70/90 membrane translocation, HMGB1 and ATP release. ADC treatment reprograms the tumor immune microenvironment to a proinflammatory state with increased macrophage and T cell infiltration, and macrophage or T cell inhibition impairs ADC efficacy in vivo.","method":"In vitro ICD biomarker assays (calreticulin, HSPs, HMGB1, ATP); syngeneic allograft vaccination/rechallenge; RNA sequencing, cytokine arrays, CyTOF, flow cytometry of TME; genetic/antibody inhibition of macrophages/T cells in vivo","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ICD biomarkers, in vivo vaccination, immune profiling, functional immune depletion) establishing mechanistic pathway","pmids":["36460335"],"is_preprint":false},{"year":2024,"finding":"GPC2 expression in retinoblastoma is driven by the E2F1 transcription factor, establishing a tumor-specific regulatory mechanism distinct from the MYCN-driven expression in neuroblastoma.","method":"GPC2 expression studies in retinoblastoma patient samples and cellular models with E2F1 transcription factor analysis","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct experimental analysis in cellular models and patient samples, single lab, limited methodological detail in abstract","pmids":["38864848"],"is_preprint":false},{"year":2024,"finding":"GPC2 promotes prostate cancer cell proliferation, migration, and invasion through MDK-mediated activation of the PI3K/AKT signaling pathway. Overexpression of MDK rescues the proliferation, migration, and invasion defects caused by GPC2 knockdown, placing GPC2 upstream of MDK in the PI3K/AKT pathway.","method":"GPC2 knockdown and overexpression in prostate cancer cell lines; MDK rescue (overexpression) experiments; PI3K/AKT pathway activity assays; proliferation, migration, invasion assays","journal":"Functional & integrative genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by rescue experiment, multiple cellular assays, single lab","pmids":["39014225"],"is_preprint":false},{"year":2025,"finding":"Tumor-infiltrating myeloid-derived suppressor cells (MDSCs), recruited by CXCL1/2 chemokines, directly inhibit GPC2 CAR T cell activation, proliferation, and cytotoxicity in neuroblastoma. Engineering GPC2 CAR T cells to express CXCR2 (the CXCL1/2 receptor) enhances their migration toward CXCL1/2 gradients, improves anti-neuroblastoma efficacy, and reduces MDSC levels in the tumor microenvironment.","method":"Immune profiling of syngeneic allografts; ex vivo MDSC inhibition assays; CXCR2-armored CAR T cell engineering with migration and cytotoxicity assays in vitro and in vivo","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic epistasis (MDSC-CAR T cell axis) with functional rescue via CXCR2 engineering, single lab, multiple orthogonal assays","pmids":["40437756"],"is_preprint":false}],"current_model":"GPC2 (cerebroglycan) is a GPI-anchored heparan sulfate proteoglycan expressed on the surface of developing neurons (polarized to axons/growth cones) and re-expressed as an oncofetal antigen in neuroblastoma and other pediatric cancers; its tumor expression is transcriptionally driven by MYCN (in neuroblastoma) or E2F1 (in retinoblastoma), it is required for neuroblastoma proliferation, and in prostate cancer it promotes PI3K/AKT signaling via MDK; the D3 antibody binds a conformational extracellular epitope (resolved at 3.3 Å), and GPC2-directed ADCs kill tumor cells via DNA damage/apoptosis while also inducing immunogenic cell death that recruits macrophages and T cells to the tumor microenvironment."},"narrative":{"mechanistic_narrative":"GPC2 (cerebroglycan) is a GPI-anchored heparan sulfate proteoglycan that functions in nervous system development and is re-deployed as an oncofetal cell-surface antigen in pediatric cancers [PMID:8294498, PMID:28898695]. During neural development it is expressed transiently in immature neurons around final mitosis and is polarized to axons and growth cones during active axon outgrowth, consistent with a role in axon growth or guidance [PMID:8294498, PMID:9133438]. In neuroblastoma, GPC2 surface expression is driven by MYCN transcriptional activation and somatic gain of the locus, and the protein is required for tumor cell proliferation [PMID:28898695]; an analogous tumor-specific program operates in retinoblastoma through the E2F1 transcription factor [PMID:38864848]. In prostate cancer, GPC2 acts upstream of MDK to activate PI3K/AKT signaling and drive proliferation, migration, and invasion [PMID:39014225]. Its restricted, tumor-associated surface display makes it a tractable immunotherapy target: a D3 antibody recognizes a conformational extracellular epitope resolved by crystallography, and the corresponding pyrrolobenzodiazepine ADC kills tumor cells via DNA damage and apoptosis [PMID:34337560] while triggering immunogenic cell death that reprograms the tumor microenvironment toward macrophage and T cell infiltration [PMID:36460335]. GPC2-directed CAR T cell efficacy is constrained by CXCL1/2-recruited myeloid-derived suppressor cells, a barrier that can be overcome by CXCR2 engineering [PMID:40437756].","teleology":[{"year":1994,"claim":"Established GPC2 as a distinct molecular entity by cloning it as a GPI-anchored heparan sulfate proteoglycan of the glypican family with developmentally restricted neural expression.","evidence":"Molecular cloning, sequence analysis, and in situ hybridization","pmids":["8294498"],"confidence":"High","gaps":["Functional consequence of GPI anchorage and HS attachment not tested","No binding partners or signaling role identified"]},{"year":1997,"claim":"Resolved the subcellular distribution of the protein, showing axon/growth-cone polarization that ties GPC2 to active axon growth rather than mature neuronal function.","evidence":"Monospecific antibody immunohistochemistry in hippocampal neurons at defined developmental stages","pmids":["9133438"],"confidence":"Medium","gaps":["Causal role in axon guidance not demonstrated by loss-of-function","Molecular mediators of polarized targeting unknown"]},{"year":2017,"claim":"Connected GPC2 oncofetal re-expression to an oncogenic driver and to tumor cell fitness, defining it as a candidate neuroblastoma target.","evidence":"RNA-seq, copy-number analysis, MYCN transcriptional assays, and knockdown with proliferation readout","pmids":["28898695"],"confidence":"Medium","gaps":["Downstream proliferative mechanism in neuroblastoma not defined","Direct MYCN binding at the locus not fully resolved"]},{"year":2021,"claim":"Defined the molecular basis of tumor-selective targeting by mapping a conformational D3 epitope and validating an ADC kill mechanism.","evidence":"3.3 Å crystal structure of D3-GPC2-Fab/GPC2 plus cytotoxicity assays with DNA damage/apoptosis readouts","pmids":["34337560"],"confidence":"High","gaps":["Structural basis of GPC2's native ligand interactions still unknown","Determinants of tumor- vs normal-tissue epitope specificity not fully characterized"]},{"year":2022,"claim":"Extended ADC mechanism from direct cytotoxicity to immune engagement, showing GPC2 ADC triggers immunogenic cell death and remodels the tumor immune microenvironment.","evidence":"ICD biomarker assays, syngeneic vaccination/rechallenge, immune profiling (RNA-seq, CyTOF, flow), and in vivo immune depletion","pmids":["36460335"],"confidence":"High","gaps":["Antigen-specific adaptive immunity to GPC2 not directly proven","Durability of immune reprogramming across tumor types untested"]},{"year":2024,"claim":"Showed that tumor-specific GPC2 transcriptional control is context-dependent, with E2F1 driving expression in retinoblastoma distinct from MYCN in neuroblastoma.","evidence":"Expression analysis in retinoblastoma patient samples and cellular models with E2F1 assessment","pmids":["38864848"],"confidence":"Medium","gaps":["Direct E2F1 occupancy at the GPC2 promoter not shown","Functional requirement for GPC2 in retinoblastoma not tested"]},{"year":2024,"claim":"Placed GPC2 in a defined signaling pathway by demonstrating it acts upstream of MDK to activate PI3K/AKT and drive malignant phenotypes in prostate cancer.","evidence":"Knockdown/overexpression with MDK rescue and PI3K/AKT pathway and proliferation/migration/invasion assays","pmids":["39014225"],"confidence":"Medium","gaps":["Physical GPC2-MDK interaction not directly demonstrated","Whether the MDK/PI3K-AKT axis operates in neuroblastoma unknown"]},{"year":2025,"claim":"Identified an immune-suppressive barrier to GPC2 cell therapy and an engineering solution, showing CXCL1/2-recruited MDSCs inhibit CAR T cells and CXCR2 arming restores efficacy.","evidence":"Syngeneic immune profiling, ex vivo MDSC inhibition, and CXCR2-armored CAR T migration/cytotoxicity assays in vitro and in vivo","pmids":["40437756"],"confidence":"Medium","gaps":["Generalizability of MDSC suppression across patient tumors unknown","Long-term persistence and safety of CXCR2-armored CAR T not established"]},{"year":null,"claim":"The native ligand-binding and signaling function of GPC2 in normal axon development, and whether this overlaps with its tumor-promoting MDK/PI3K-AKT activity, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No direct molecular function assigned to the heparan sulfate chains","Mechanistic link between developmental axon role and oncogenic signaling unexplored"]}],"mechanism_profile":{"molecular_activity":[],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1]}],"complexes":[],"partners":["MDK"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8N158","full_name":"Glypican-2","aliases":[],"length_aa":579,"mass_kda":62.8,"function":"Cell surface proteoglycan that bears heparan sulfate. May fulfill a function related to the motile behaviors of developing neurons (By similarity)","subcellular_location":"Secreted, extracellular space","url":"https://www.uniprot.org/uniprotkb/Q8N158/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GPC2","classification":"Not Classified","n_dependent_lines":43,"n_total_lines":1208,"dependency_fraction":0.03559602649006623},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GPC2","total_profiled":1310},"omim":[{"mim_id":"618446","title":"GLYPICAN 2; GPC2","url":"https://www.omim.org/entry/618446"},{"mim_id":"162096","title":"MIDKINE; MDK","url":"https://www.omim.org/entry/162096"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":4.8},{"tissue":"skin 1","ntpm":5.5},{"tissue":"testis","ntpm":11.4}],"url":"https://www.proteinatlas.org/search/GPC2"},"hgnc":{"alias_symbol":["cerebroglycan","FLJ38962","DKFZp547M109"],"prev_symbol":[]},"alphafold":{"accession":"Q8N158","domains":[{"cath_id":"-","chopping":"75-351_387-452","consensus_level":"medium","plddt":92.7927,"start":75,"end":452}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N158","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N158-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N158-F1-predicted_aligned_error_v6.png","plddt_mean":79.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GPC2","jax_strain_url":"https://www.jax.org/strain/search?query=GPC2"},"sequence":{"accession":"Q8N158","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N158.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N158/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N158"}},"corpus_meta":[{"pmid":"28898695","id":"PMC_28898695","title":"Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.","date":"2017","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/28898695","citation_count":179,"is_preprint":false},{"pmid":"8294498","id":"PMC_8294498","title":"Cerebroglycan: an integral membrane heparan sulfate proteoglycan that is unique to the developing nervous system and expressed specifically during neuronal differentiation.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8294498","citation_count":165,"is_preprint":false},{"pmid":"34971569","id":"PMC_34971569","title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.","date":"2021","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/34971569","citation_count":149,"is_preprint":false},{"pmid":"9133438","id":"PMC_9133438","title":"Cerebroglycan, a developmentally regulated cell-surface heparan sulfate proteoglycan, is expressed on developing axons and growth cones.","date":"1997","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9133438","citation_count":62,"is_preprint":false},{"pmid":"35852863","id":"PMC_35852863","title":"An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35852863","citation_count":56,"is_preprint":false},{"pmid":"36167467","id":"PMC_36167467","title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36167467","citation_count":48,"is_preprint":false},{"pmid":"34337560","id":"PMC_34337560","title":"A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.","date":"2021","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34337560","citation_count":32,"is_preprint":false},{"pmid":"36631162","id":"PMC_36631162","title":"Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36631162","citation_count":31,"is_preprint":false},{"pmid":"36460335","id":"PMC_36460335","title":"GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36460335","citation_count":30,"is_preprint":false},{"pmid":"38864848","id":"PMC_38864848","title":"Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/38864848","citation_count":11,"is_preprint":false},{"pmid":"40437756","id":"PMC_40437756","title":"Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells.","date":"2025","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40437756","citation_count":8,"is_preprint":false},{"pmid":"39014225","id":"PMC_39014225","title":"GPC2 promotes prostate cancer progression via MDK-mediated activation of PI3K/AKT signaling pathway.","date":"2024","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/39014225","citation_count":8,"is_preprint":false},{"pmid":"36920409","id":"PMC_36920409","title":"Association between GPC2 polymorphisms and neuroblastoma risk in Chinese children.","date":"2023","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/36920409","citation_count":6,"is_preprint":false},{"pmid":"40569285","id":"PMC_40569285","title":"GPC2-Targeted CAR T Cells Engineered with NFAT-Inducible Membrane-Tethered IL15/IL21 Exhibit Enhanced Activity against Neuroblastoma.","date":"2025","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/40569285","citation_count":5,"is_preprint":false},{"pmid":"38904586","id":"PMC_38904586","title":"Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.","date":"2024","source":"Cytotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/38904586","citation_count":5,"is_preprint":false},{"pmid":"35233466","id":"PMC_35233466","title":"GPC2 deficiency inhibits cell growth and metastasis in colon adenocarcinoma.","date":"2022","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/35233466","citation_count":4,"is_preprint":false},{"pmid":"41026583","id":"PMC_41026583","title":"D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer.","date":"2025","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/41026583","citation_count":2,"is_preprint":false},{"pmid":"41159102","id":"PMC_41159102","title":"GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts.","date":"2025","source":"Molecular therapy. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41159102","citation_count":2,"is_preprint":false},{"pmid":"41027430","id":"PMC_41027430","title":"Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density.","date":"2025","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41027430","citation_count":0,"is_preprint":false},{"pmid":"42231577","id":"PMC_42231577","title":"Development of novel GPC2-directed radiotheranostics and CAR T-cell therapy for neuroblastoma.","date":"2026","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/42231577","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12794,"output_tokens":2216,"usd":0.035811,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9308,"output_tokens":2683,"usd":0.056807,"stage2_stop_reason":"end_turn"},"total_usd":0.092618,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"Cerebroglycan (GPC2) is a glycosylphosphatidylinositol (GPI)-anchored heparan sulfate proteoglycan (HSPG) with a predicted molecular mass of 58.6 kD and five potential heparan sulfate attachment sites. Together with glypican, it defines a family of integral membrane HSPGs characterized by GPI linkage and a conserved pattern of 14 cysteine residues. Expression is restricted to the developing nervous system, appearing transiently in immature neurons around the time of final mitosis and disappearing after cell migration and axon outgrowth.\",\n      \"method\": \"Molecular cloning, sequence analysis, in situ hybridization\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — molecular cloning with structural characterization (predicted domains, GPI anchor, cysteine pattern) plus in situ hybridization expression pattern; foundational characterization paper replicated by subsequent studies\",\n      \"pmids\": [\"8294498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Cerebroglycan (GPC2) protein is strongly polarized to axons and growth cones of developing neurons, excluded from the somatodendritic compartment, and is present on axon tracts during active axon growth but absent after axons reach their targets, consistent with a role in axon growth or guidance.\",\n      \"method\": \"Monospecific antibody localization by immunohistochemistry in vivo and in vitro; analysis of hippocampal neurons at defined developmental stages\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein localization with monospecific antibodies in multiple tissue contexts, single lab\",\n      \"pmids\": [\"9133438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPC2 expression in neuroblastoma is driven by MYCN transcriptional activation and/or somatic gain of the GPC2 locus. GPC2 is required for neuroblastoma cell proliferation, as demonstrated by loss-of-function experiments showing reduced proliferation upon GPC2 knockdown.\",\n      \"method\": \"RNA sequencing, somatic copy-number analysis, MYCN transcriptional activation assays, loss-of-function (knockdown) with proliferation readout\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (transcriptomics, genomics, functional knockdown), single lab\",\n      \"pmids\": [\"28898695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The GPC2-directed antibody D3 binds a conformational, tumor-specific epitope on the extracellular domain of GPC2, as determined by crystal structure of the D3-GPC2-Fab/GPC2 complex at 3.3 Å resolution. The ADC (D3-GPC2-PBD) induces DNA damage, apoptosis, and bystander cell killing in neuroblastoma and small-cell lung cancer cells.\",\n      \"method\": \"Crystal structure determination at 3.3 Å; in vitro and in vivo cytotoxicity assays with DNA damage and apoptosis readouts\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional validation (ADC mechanism via DNA damage/apoptosis), multiple orthogonal assays in single rigorous study\",\n      \"pmids\": [\"34337560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"D3-GPC2-PBD ADC induces immunogenic cell death (ICD) in GPC2-expressing neuroblastoma cells, evidenced by calreticulin and HSP70/90 membrane translocation, HMGB1 and ATP release. ADC treatment reprograms the tumor immune microenvironment to a proinflammatory state with increased macrophage and T cell infiltration, and macrophage or T cell inhibition impairs ADC efficacy in vivo.\",\n      \"method\": \"In vitro ICD biomarker assays (calreticulin, HSPs, HMGB1, ATP); syngeneic allograft vaccination/rechallenge; RNA sequencing, cytokine arrays, CyTOF, flow cytometry of TME; genetic/antibody inhibition of macrophages/T cells in vivo\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ICD biomarkers, in vivo vaccination, immune profiling, functional immune depletion) establishing mechanistic pathway\",\n      \"pmids\": [\"36460335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GPC2 expression in retinoblastoma is driven by the E2F1 transcription factor, establishing a tumor-specific regulatory mechanism distinct from the MYCN-driven expression in neuroblastoma.\",\n      \"method\": \"GPC2 expression studies in retinoblastoma patient samples and cellular models with E2F1 transcription factor analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct experimental analysis in cellular models and patient samples, single lab, limited methodological detail in abstract\",\n      \"pmids\": [\"38864848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GPC2 promotes prostate cancer cell proliferation, migration, and invasion through MDK-mediated activation of the PI3K/AKT signaling pathway. Overexpression of MDK rescues the proliferation, migration, and invasion defects caused by GPC2 knockdown, placing GPC2 upstream of MDK in the PI3K/AKT pathway.\",\n      \"method\": \"GPC2 knockdown and overexpression in prostate cancer cell lines; MDK rescue (overexpression) experiments; PI3K/AKT pathway activity assays; proliferation, migration, invasion assays\",\n      \"journal\": \"Functional & integrative genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by rescue experiment, multiple cellular assays, single lab\",\n      \"pmids\": [\"39014225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Tumor-infiltrating myeloid-derived suppressor cells (MDSCs), recruited by CXCL1/2 chemokines, directly inhibit GPC2 CAR T cell activation, proliferation, and cytotoxicity in neuroblastoma. Engineering GPC2 CAR T cells to express CXCR2 (the CXCL1/2 receptor) enhances their migration toward CXCL1/2 gradients, improves anti-neuroblastoma efficacy, and reduces MDSC levels in the tumor microenvironment.\",\n      \"method\": \"Immune profiling of syngeneic allografts; ex vivo MDSC inhibition assays; CXCR2-armored CAR T cell engineering with migration and cytotoxicity assays in vitro and in vivo\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic epistasis (MDSC-CAR T cell axis) with functional rescue via CXCR2 engineering, single lab, multiple orthogonal assays\",\n      \"pmids\": [\"40437756\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GPC2 (cerebroglycan) is a GPI-anchored heparan sulfate proteoglycan expressed on the surface of developing neurons (polarized to axons/growth cones) and re-expressed as an oncofetal antigen in neuroblastoma and other pediatric cancers; its tumor expression is transcriptionally driven by MYCN (in neuroblastoma) or E2F1 (in retinoblastoma), it is required for neuroblastoma proliferation, and in prostate cancer it promotes PI3K/AKT signaling via MDK; the D3 antibody binds a conformational extracellular epitope (resolved at 3.3 Å), and GPC2-directed ADCs kill tumor cells via DNA damage/apoptosis while also inducing immunogenic cell death that recruits macrophages and T cells to the tumor microenvironment.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GPC2 (cerebroglycan) is a GPI-anchored heparan sulfate proteoglycan that functions in nervous system development and is re-deployed as an oncofetal cell-surface antigen in pediatric cancers [#0, #2]. During neural development it is expressed transiently in immature neurons around final mitosis and is polarized to axons and growth cones during active axon outgrowth, consistent with a role in axon growth or guidance [#0, #1]. In neuroblastoma, GPC2 surface expression is driven by MYCN transcriptional activation and somatic gain of the locus, and the protein is required for tumor cell proliferation [#2]; an analogous tumor-specific program operates in retinoblastoma through the E2F1 transcription factor [#5]. In prostate cancer, GPC2 acts upstream of MDK to activate PI3K/AKT signaling and drive proliferation, migration, and invasion [#6]. Its restricted, tumor-associated surface display makes it a tractable immunotherapy target: a D3 antibody recognizes a conformational extracellular epitope resolved by crystallography, and the corresponding pyrrolobenzodiazepine ADC kills tumor cells via DNA damage and apoptosis [#3] while triggering immunogenic cell death that reprograms the tumor microenvironment toward macrophage and T cell infiltration [#4]. GPC2-directed CAR T cell efficacy is constrained by CXCL1/2-recruited myeloid-derived suppressor cells, a barrier that can be overcome by CXCR2 engineering [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established GPC2 as a distinct molecular entity by cloning it as a GPI-anchored heparan sulfate proteoglycan of the glypican family with developmentally restricted neural expression.\",\n      \"evidence\": \"Molecular cloning, sequence analysis, and in situ hybridization\",\n      \"pmids\": [\"8294498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of GPI anchorage and HS attachment not tested\", \"No binding partners or signaling role identified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved the subcellular distribution of the protein, showing axon/growth-cone polarization that ties GPC2 to active axon growth rather than mature neuronal function.\",\n      \"evidence\": \"Monospecific antibody immunohistochemistry in hippocampal neurons at defined developmental stages\",\n      \"pmids\": [\"9133438\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal role in axon guidance not demonstrated by loss-of-function\", \"Molecular mediators of polarized targeting unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected GPC2 oncofetal re-expression to an oncogenic driver and to tumor cell fitness, defining it as a candidate neuroblastoma target.\",\n      \"evidence\": \"RNA-seq, copy-number analysis, MYCN transcriptional assays, and knockdown with proliferation readout\",\n      \"pmids\": [\"28898695\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream proliferative mechanism in neuroblastoma not defined\", \"Direct MYCN binding at the locus not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the molecular basis of tumor-selective targeting by mapping a conformational D3 epitope and validating an ADC kill mechanism.\",\n      \"evidence\": \"3.3 Å crystal structure of D3-GPC2-Fab/GPC2 plus cytotoxicity assays with DNA damage/apoptosis readouts\",\n      \"pmids\": [\"34337560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of GPC2's native ligand interactions still unknown\", \"Determinants of tumor- vs normal-tissue epitope specificity not fully characterized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended ADC mechanism from direct cytotoxicity to immune engagement, showing GPC2 ADC triggers immunogenic cell death and remodels the tumor immune microenvironment.\",\n      \"evidence\": \"ICD biomarker assays, syngeneic vaccination/rechallenge, immune profiling (RNA-seq, CyTOF, flow), and in vivo immune depletion\",\n      \"pmids\": [\"36460335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Antigen-specific adaptive immunity to GPC2 not directly proven\", \"Durability of immune reprogramming across tumor types untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed that tumor-specific GPC2 transcriptional control is context-dependent, with E2F1 driving expression in retinoblastoma distinct from MYCN in neuroblastoma.\",\n      \"evidence\": \"Expression analysis in retinoblastoma patient samples and cellular models with E2F1 assessment\",\n      \"pmids\": [\"38864848\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct E2F1 occupancy at the GPC2 promoter not shown\", \"Functional requirement for GPC2 in retinoblastoma not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed GPC2 in a defined signaling pathway by demonstrating it acts upstream of MDK to activate PI3K/AKT and drive malignant phenotypes in prostate cancer.\",\n      \"evidence\": \"Knockdown/overexpression with MDK rescue and PI3K/AKT pathway and proliferation/migration/invasion assays\",\n      \"pmids\": [\"39014225\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physical GPC2-MDK interaction not directly demonstrated\", \"Whether the MDK/PI3K-AKT axis operates in neuroblastoma unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified an immune-suppressive barrier to GPC2 cell therapy and an engineering solution, showing CXCL1/2-recruited MDSCs inhibit CAR T cells and CXCR2 arming restores efficacy.\",\n      \"evidence\": \"Syngeneic immune profiling, ex vivo MDSC inhibition, and CXCR2-armored CAR T migration/cytotoxicity assays in vitro and in vivo\",\n      \"pmids\": [\"40437756\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability of MDSC suppression across patient tumors unknown\", \"Long-term persistence and safety of CXCR2-armored CAR T not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The native ligand-binding and signaling function of GPC2 in normal axon development, and whether this overlaps with its tumor-promoting MDK/PI3K-AKT activity, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct molecular function assigned to the heparan sulfate chains\", \"Mechanistic link between developmental axon role and oncogenic signaling unexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MDK\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}